LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Incyte Corp

Закрыт

СекторЗдравоохранение

84.59 0.77

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

83.51

Макс.

85.89

Ключевые показатели

By Trading Economics

Доход

247M

405M

Продажи

163M

1.2B

P/E

Средняя по отрасли

19.655

35.293

Прибыль на акцию

1.16

Рентабельность продаж

33.319

Сотрудники

2,617

EBITDA

324M

582M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+0.42% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

28 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.7B

16B

Предыдущая цена открытия

83.82

Предыдущая цена закрытия

84.59

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Incyte Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

17 сент. 2025 г., 23:01 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 сент. 2025 г., 22:48 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 сент. 2025 г., 21:59 UTC

Отчет

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 сент. 2025 г., 23:44 UTC

Обсуждения рынка

Nikkei May Rise as Yen Weakens -- Market Talk

17 сент. 2025 г., 23:39 UTC

Обсуждения рынка

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 сент. 2025 г., 22:19 UTC

Приобретения, слияния, поглощения

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 сент. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 сент. 2025 г., 21:00 UTC

Отчет

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 сент. 2025 г., 19:07 UTC

Обсуждения рынка

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 сент. 2025 г., 18:43 UTC

Обсуждения рынка

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 сент. 2025 г., 18:38 UTC

Обсуждения рынка

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 сент. 2025 г., 18:20 UTC

Обсуждения рынка

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 сент. 2025 г., 18:14 UTC

Обсуждения рынка

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 сент. 2025 г., 17:59 UTC

Обсуждения рынка

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 сент. 2025 г., 17:15 UTC

Приобретения, слияния, поглощения

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 сент. 2025 г., 17:06 UTC

Приобретения, слияния, поглощения

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 сент. 2025 г., 16:51 UTC

Отчет

Correct: Exor 1H Net Loss -EUR624M

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 сент. 2025 г., 16:25 UTC

Отчет

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 сент. 2025 г., 16:23 UTC

Отчет

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение c конкурентами

Изменение цены

Incyte Corp Прогноз

Целевая цена

By TipRanks

0.42% рост

Прогноз на 12 месяцев

Средняя 84.25 USD  0.42%

Максимум 110 USD

Минимум 60 USD

Основано на мнении 17 аналитиков Wall Street, спрогнозировавших целевые цены для Incyte Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

17 ratings

8

Покупка

8

Удержание

1

Продажа

Техническая оценка

By Trading Central

59.52 / 62.66Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat